According to the analyst analysis, the sales of Paclitaxel in the Chinese market increased year by year from 2016 to 2019. Among them, the annual growth rate of 40.86% was the highest in 2019, from CNY2.168 billion in 2018 to CNY3.053 billion in 2019. In 2020, the hospital's overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers. With the sharp price reduction in centralized procurement, Paclitaxel sales have declined with a growth rate of -18.64%. The CAGR of Paclitaxel sales in the Chinese market from 2016 to 2020 was 7.16%.
The analyst analyzes that the Paclitaxel sales in China will increase steadily with the increase in breast cancer patients from 2021 to 2025. In 2020, the number of new cases of breast cancer worldwide reached 2.26 million, and breast cancer is the most commonly diagnosed cancer, overtaking lung cancer. Therefore, the sales and sales volume of Paclitaxel for the treatment of breast cancer will increase accordingly with the increase in the number of patients diagnosed. Furthermore, Paclitaxel will be included in the National Drug Price Negotiation in 2021, and then its sales will keep a continuous rise. In addition, the effective alleviation of the Covid-19 epidemic will lead to a recovery growth in the sales of Paclitaxel.
Topics Covered:
- The impact of COVID-19 on China's Paclitaxel market
- Sales value of China's Paclitaxel 2016-2020
- Competitive landscape of China's Paclitaxel market
- Prices of Paclitaxel in China
- Prices of Paclitaxel in China by regions and manufacturers
- Analysis of factors affecting the development of China's Paclitaxel market
- Prospect of China's Paclitaxel market from 2021 to 2025
Table of Contents
Samples
LOADING...
Companies Mentioned
- Beistol-Myers Squibb S.r.l.
- CSPC Ouyi Pharmaceutical Group Co., Ltd
- Hospira Australia Pty Ltd
- Jiangsu Hengrui Pharmaceutical Co., Ltd
- Nanjing Luye Pharmaceutical Co., Ltd
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 50 |
Published | May 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 1883.65 Million |
Forecasted Market Value ( CNY | CNY 4000.6 Million |
Compound Annual Growth Rate | 8.7% |
Regions Covered | China |
No. of Companies Mentioned | 5 |